Nationwide Molecular Surveillance of Pandemic H1N1 Influenza A Virus Genomes: Canada, 2009 by Graham, Morag et al.
Nationwide Molecular Surveillance of Pandemic H1N1
Influenza A Virus Genomes: Canada, 2009
Morag Graham
1,2*, Binhua Liang
1, Gary Van Domselaar
1,2,3, Nathalie Bastien
1, Carole Beaudoin
1,4,
Shaun Tyler
1, Brynn Kaplen
1, Erika Landry
1, the National Influenza A/H1N1pdm Genomics Study Team
(NIGST)
", Yan Li
1,2
1National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada, 2Department of Medical Microbiology, University of Manitoba,
Winnipeg, Manitoba, Canada, 3Department of Computer Science, University of Manitoba, Winnipeg, Manitoba, Canada, 4Department of Community Health Sciences,
University of Manitoba, Winnipeg, Manitoba, Canada
Abstract
Background: In April 2009, a novel triple-reassortant swine influenza A H1N1 virus (‘‘A/H1N1pdm’’; also known as SOIV) was
detected and spread globally as the first influenza pandemic of the 21
st century. Sequencing has since been conducted at
an unprecedented rate globally in order to monitor the diversification of this emergent virus and to track mutations that
may affect virus behavior.
Methodology/Principal Findings: By Sanger sequencing, we determined consensus whole-genome sequences for A/
H1N1pdm viruses sampled nationwide in Canada over 33 weeks during the 2009 first and second pandemic waves. A total
of 235 virus genomes sampled from unique subjects were analyzed, providing insight into the temporal and spatial
trajectory of A/H1N1pdm lineages within Canada. Three clades (2, 3, and 7) were identifiable within the first two weeks of A/
H1N1pdm appearance, with clades 5 and 6 appearing thereafter; further diversification was not apparent. Only two viral
sites displayed evidence of adaptive evolution, located in hemagglutinin (HA) corresponding to D222 in the HA receptor-
binding site, and to E374 at HA2-subunit position 47. Among the Canadian sampled viruses, we observed notable genetic
diversity (1.47610
23 amino acid substitutions per site) in the gene encoding PB1, particularly within the viral genomic RNA
(vRNA)-binding domain (residues 493–757). This genome data set supports the conclusion that A/H1N1pdm is evolving but
not excessively relative to other H1N1 influenza A viruses. Entropy analysis was used to investigate whether any mutated A/
H1N1pdm protein residues were associated with infection severity; however no virus genotypes were observed to trend
with infection severity. One virus that harboured heterozygote coding mutations, including PB2 D567D/G, was attributed to
a severe and potentially mixed infection; yet the functional significance of this PB2 mutation remains unknown.
Conclusions/Significance: These findings contribute to enhanced understanding of Influenza A/H1N1pdm viral dynamics.
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Introduction
Influenza viruses (family Orthomyxoviridae) possess a segmented,
negativepolarity,single-strandedRNAgenomeandlipid-enveloped
virions [1]. Genetic diversity in influenza virus results from a high
replication error rate associated with low-fidelity RNA polymerase,
and the reshuffling (or reassortment) of gene segments among co-
infecting strains [1–3]. These genetic shifts periodically lead to
antigenically novel strains that emerge as pandemic viruses [1]. In
April2009,a noveltriple-reassortantswineinfluenzaA/H1N1virus
(alsoknownasSOIV)wasdetected,withhumancasesfirstidentified
in Mexico and California [4]; thereafter, the pandemic 2009
influenza A (H1N1) virus (designated hereafter as ‘‘A/H1N1pdm’’)
spread globally as the first influenza pandemic of the 21
st century.
During the 2009–2010 pandemic, A/H1N1pdm became the
dominant circulating virus. Efficient human-to-human transmission
was observed, with clinical attack rates of 20–50% [5]. Laboratory-
confirmed A/H1N1pdm cases occurred in over 214 countries, with
over 18,114 worldwide deaths attributed as of 23 May 2010 [6].
The 13.5-kb influenza A virus genome is comprised of eight
segments coding for up to 11 viral proteins: three proteins
encoding the RNA-dependent RNA polymerase complex (PA,
PB1, and PB2); nucleoprotein (NP); nonstructural (NS1 and NEP
(formerly known as NS2)) and matrix (M1 and M2) proteins, and
two glycoproteins, hemagglutinin (HA) and neuraminidase (NA)
[1]. The pro-apoptotic but nonstructural polymerase basic 1 frame
2 (PB1-F2) protein encoded by segment 2 terminates prematurely
in A/H1N1pdm viruses [7].
The Canadian provinces of Quebec (PQ) and Ontario (ON) first
identified cases of influenza-like illness (ILI) with travel histories or
exposure to travelers returning from Mexico within 2 weeks of
outbreak detection (weeks 03–04 relative to the global outbreak
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British Columbia (BC), Alberta (AB) and Nova Scotia (NS) [8] and
then spread across Canada in two distinct waves. According to
Canada’s national sentinel surveillance system (FluWatch), during
wave 1 spanning global outbreak weeks 03 to 22 (April 1 to August
29 2009, representing FluWatch weeks 15 to 34) 6676 laboratory-
confirmed cases were attributed to A/H1N1pdm. As of June 19
2010, 33,521 laboratory-confirmed cases had been attributed to
A/H1N1pdm during wave 2 (commencing August 30 2009).
Hence, a sum total of 40,197 A/H1N1pdm cases were reported to
the Public Health Agency of Canada (PHAC). However, as neither
confirmation nor reporting of clinically diagnosed cases was
required, this figure significantly underestimates the true extent of
A/H1N1pdm encountered in Canada. As elsewhere, the vast
majority of A/H1N1pdm-infected Canadians experienced pre-
dominantly mild uncomplicated, self-limiting, upper respiratory
tract illness; fewer than 20% of cases required hospitalization
(Source: FluWatch).
The A/H1N1pdm virus continues to circulate worldwide,
giving rise to concerns about genotypic diversity that might evolve
to enhance virus transmissibility and/or pathogenicity and affect
vaccine efficacy. An earlier study noted early diversification of the
A/H1N1pdm virus into seven distinct lineages, designated as
clades 1–7, with spatial patterning within 19 weeks of the
pandemic’s initiation [9]. Herein, we report whole-genome
investigations for A/H1N1pdm viruses sampled nationwide over
a broader timeframe of 33 weeks (April 16 2009 - December 5
2009) during the 2009 first and second waves in Canada;
representing n=178 and 57 unique virus genomes, respectively.
We then conducted analyses to gain insight into 1) how A/
H1N1pdm influenza spread spatially and temporally during the
nationwide epidemic, and 2) whether mutated A/H1N1pdm
protein residues influenced infection severity. Understanding the
spatial and temporal spread of A/H1N1pdm lineages in Canada
may provide insights into disease trajectory for future influenza
pandemic planning. Determining any correlation between mutat-
ed protein residues and infection severity is important for vaccine
development, and could be important for resource allocation
should identified mutations arise in at risk populations.
Results
Multiple introductions of A/H1N1pdm into Canada,
generating complex spatial patterns
Supplemented with 1198 whole-genome sequences available
globally as of June 2 2010, the concatenated A/H1N1pdm
sequences sampled from Canadian provinces and territories
(n=235) were subjected to phylogenetic analysis. Our phyloge-
netic inference supports that multiple A/H1N1pdm lineages were
introduced into Canada generating complex spatial patterns
(Figures 1, 2 and 3). Presence in all Canadian sequences of non-
clade 1 mutations (namely HA (P83S [P100S], and I321V
[I338V]) and PA (P224S)) agrees with prior reports of limited
geographic dissemination of clade 1 isolates [9].
The first Canadian specimen (RV1595/09 (PQ) representing a
mild case acquired April 16 2009 or week 03 of the global
outbreak) belonged to clade 2 (Tables S1 and S2). Characterized
by two amino acid substitutions relative to ancestor sequences: PA
(M581L) and NP (T373I), clade 2 viruses quickly disseminated
worldwide [9], and nationwide (this study). In a recent non-
phylogenetic, graph-based genealogical analysis (SeqTrack) based
on 433 HA and NA global outbreak sequences, RV1595/09
exhibited inferred ancestry dating to March 30 2009 [10], a
timeframe also shared with the first globally sampled and
sequenced A/H1N1pdm virus (clade 1; A/California/04/2009)
and 11 other viruses, including another clade 2 virus from Canada
(designated RV1644/09 from Alberta (AB) associated with a
severe infection). Clade 2 viruses represented 19.1% (45/235) of
the sampled Canadian sequences (Figure 1). However, 13 (29%)
were sampled during global outbreak week 05, representing the
first identified (and most characterized cluster) of human influenza
A/H1N1(2009) (H1N1pdm) infections in Nova Scotia (NS),
Canada. The NS genomes data set confirms prior epidemiological
data stating that all cases (all mild) had contact with a return
traveler from Mexico and transmission occurred through human-
to-human transmission from a single index case [8]. Clade 2
viruses appeared shortly thereafter in Ontario (ON) and
Saskatchewan (SK). A previous report that no isolates collected
globally were members of clade 2 following outbreak week 08 [9]
is not supported by our findings, since clade 2 viruses were present
(albeit in lower prevalence) throughout wave 1, and even as late as
outbreak week 30 during Canada’s wave 2 (Table S2).
Clade 3 (represented by A/Arizona/01/2009) was detected
globally several weeks after clades 1 and 2; although no fixed
amino acid changes are common to all clade 3 isolates [9]. Clade 3
first appeared in Canada (represented by RV1586/09 - PQ)
during week 04 with inferred ancestry in the previous week [10].
However as noted elsewhere, clade 3 also did not persist in
Canada; a sum total of only three clade 3 viruses were identified
amongst Canadian viruses in PQ (2) and Manitoba (MB) (1)
regions (Figures 1 and 3; Table S2). Interestingly, the last clade 3
virus (RV3189/09 - PQ) was not sampled until outbreak week 32.
Clade 5, characterized by amino acid changes in the NP
(V100I) and NA (V106I and N248D) was only observed twice in
Canada (RV1758/09 and RV1954/09) in PQ during outbreak
weeks 06 and 08, respectively (Figures 1 and 3; Table S2) with
inferred ancestries in the same week 06 [10].
Clade 6, characterized by two non-epitope, unique amino acid
substitutions in HA (K-15E [K2E] and Q293H [Q310H]),
appeared later in Canada starting in week 06 (RV1765/09 -
MB). Clade 6 viruses accounted for 24.3% (57/235) of the
sampled Canadian viruses. Amongst this study’s sequenced data
set, clade 6 viruses dominated in MB (n=40) up to outbreak week
11. Sequenced clade 6 viruses also were detected in 8 other regions
(AB, New Brunswick (NB), Newfoundland and Labrador (NFL),
NS, Nunavut (NU), Northwest Territories (NWT), ON, and SK),
but were fewer (range: 1–6) (Figures 1 and 3; Table S2).
Clade 7 originated late in March 2009 and appeared in New
York a few weeks after clades 1 and 2 were isolated in Mexico and
California [9]. Clade 7 sequences, characterized by fixed amino
acid changes in the NP (V100I) and NA (V106I and N248D) that
are also found in clades 5 and 6 as well as by unique amino acid
changes in mature HA (S203T) and NS1 (I123V), first appeared in
Canada in ON (RV1526/09, RV1527/09, and RV1529/09)
during global outbreak week 04 (Table S3). RV1527/09 exhibited
inferred ancestry in the same week [10]. Clade 7, globally the most
widely circulating clade, also represented the most heterogeneous
cluster and the largest fraction - 54.5% (128/235) - of the sampled
Canadian sequences (Figure 2). Clade 7 viruses were spatially
distributed across 9 sampled regions (AB, British Columbia (BC),
MB, NB, NFL, NS, ON, PQ, and SK) (Figure 1; Table S2).
This study’s whole-genome data set provides high density
sampling of viruses circulating in Canada throughout weeks 05
through 19 of the global A/H1N1pdm wave 1 outbreak (n=168)
and additional sampling of circulating A/H1N1pdm viruses
during weeks 23 through 31 (n=42) (Figure S1), which just
precedes Canada’s wave 2 peak (occurring at outbreak week 32;
Figure S2). The distributions of A/H1N1pdm virus clades in
A/H1N1pdm Genomes in Canada
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7) were identifiable within the first two weeks of A/H1N1pdm
appearance in Canada, with clades 5 and 6 appearing two weeks
thereafter. Thus, multiple introductions of phylogenetically-
distinct A/H1N1pdm occurred into Canada from the Americas.
Further diversification in Canada beyond these five previously
described clades is not apparent within the 33 week sampling
period (Figure 3). Overall, there was limited association between
virus clades and their originating geographic regions (Figures 1
and 2), indicating multiple introductions had occurred. No
association existed between the phylogenetic positioning of the
viruses and their sampling collection week (Figure 4).
Limited A/H1N1pdm genetic diversity during temporal
and spatial spread in Canada
Phylogenetic analysis of the 235 unique whole-genomes for
Canadian A/H1N1pdm viruses sampled between April 16 and
December 5 2009 revealed polymorphic sites in all eight segments
of the viral genomes (Table 1). Coding variations are summarized
in the Supporting Information (Table S2). A sum total of 1124
synonymous (s) and 917 non-synonymous (ns) variants were
observed across the data set, corresponding to genome mean of
approximately 7.82610
24 nucleotide changes per gene site and
9.00610
24 coding substitutions per protein site. Coding variants
were non-uniformly distributed across the segments: HA (352); NA
(178); PB1 (172); NP (127); PB2 (32); PA (28); NS1 (18); M1 (4);
M2 (4), and NS2/NEP (2) (Table S2). However, A/H1N1pdm
clade-specifying variations (relative to ancestor sequences) ac-
counted for 68% (622/917) of the ns variants. Overall these
findings from Canada support that A/H1N1pdm virus is evolving,
but not excessively relative to other H1N1 influenza A viruses.
Aside from expected diversity for the antigenic viral glycopro-
teins (HA and NA), high ns/s (coding/non-coding) ratios also were
observed in the genes encoding nucleoprotein (NP) and polymer-
ase basic protein 1 (PB1) (Table S2). PB1 diversity in the Canadian
sampled A/H1N1pdm viruses was somewhat surprising given a
paucity of PB1 adaptive mutations, relative to PB2 and PA
variations, described in the literature.
In order to track the antigenic evolution of A/H1N1pdm, we
investigated potential antigenic drift in HA. Amino acid
substitutions were observed in a limited number (9) of the
Canadian viruses at characterized hemagglutinin antigenic sites:
Ca (7) - R205K in Ca1 (6) and P137S Ca2 (1); S74N in Cb (1); and
A186T in Sb (1) (Table S2) [11,12]. Herein the amino acid
residues represent the H1 numbering scheme exclusive of the
signal peptide. These specimens were collected in AB, BC, MB,
Figure 1. Geographical and clade distributions for A/H1N1pdm viruses sampled in Canada. Phylogenetic analysis was performed with
two hundred thirty five viruses sampled in Canada and linked to their corresponding clades, as shown in Figure 2.
doi:10.1371/journal.pone.0016087.g001
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unknown cases. All six of the R205K Ca1 variants were clade 6
viruses isolated in southwestern ON during wave 2 (weeks 20, 24,
26, 27 and 29); thus, could have emerged from a regional single
point introduction.
Glycosylation of HA plays a role in antigenic variation by
masking antigenic sites, conveying resistance to neutralizing
antibodies [13]. Few glycosylation variants were noted in the
Canadian sampled viruses, and most generated loss of N-
glycosylation sequons (N87K; RV1532/09; residue 104 in
propeptide) or loss of potential ‘‘Cand1’’ glycosylation sites
(N56D; N228D; Y230H in the HA1 globular head, and a mixed
site N473N/R in HA2 (RV2810/09; residue 490 in propeptide)
[11]. All of these variants were attributed to mild or unknown
influenza cases. Thus, additional N-glycosylation sequons have not
been acquired by A/H1N1pdm viruses since introduction in
Canada.
Only six coding substitutions were observed within the HA
receptor-binding site (RBS): one A186T variant in the 190-helix
(184–191); and 5 residue 222 variants (D222E and D222G) in the
220-loop (mature peptide residues 218–225). Residue 222 (225 in
H3 numbering), has garnered attention because it plays a role in
conferring specificity to a2–6 sialylated glycans present in the
human upper airway, and may modulate binding to the human
lower respiratory tract pneumocytes expressing a2–3 sialylated
glycans [14]. However, these five Canadian HA D222 variant
viruses were not geographically clustered, did not spread, and the
status of the associated infections remains unknown.
A sporadic HA variant of note, E374K (residue 391 in HA
propeptide), was observed in 8 Canadian viruses from 5 Canadian
regions spanning outbreak weeks 17 to 36. In the available HA
crystal structure, residue 374 (corresponding to HA2-subunit
position 47) is directed into the cavity where the fusion peptide
resides in the mature fusion-ready form of the HA molecule
[12,15]. Hence, this mutation may alter salt bridge patterns and
stability in a region of the HA oligomerization interface that is
important for membrane fusion. Residue 374 is also near to a
region identified in HA-neutralizing antibody structures that target
a known antigenic site in the HA stem region [16]. These eight
HA E374K viruses were associated with mild infection (1) or cases
of unknown severity (7).
NA residue positions 118, 119, 151, 152, 156, 179, 180, 223,
225, 228, 247, 277, 278, 293, 295, 368, and 402 are important for
contacting sialoligosaccharide substrates directly; participating in
catalysis, or for providing a structural framework [17]. Substitu-
tions within these sites were observed in only 2 Canadian A/
H1N1pdm viruses, namely NA E119K (RV2984/09 sampled in
global outbreak week 29) and N295S (1: RV0005-10/2009
sampled in week 36). We observed 16 distinct variations in 78
viruses at neuraminidase antigenic sites, represented by NA
residues 83–143, 156–190, 252–303, 330, 332, 340–345, 368, 370,
387–395, 400, 431–435, and 448–468 [17]. These variants were
V83M (1); S95G (4); V106I (49); E119K (1); I163V (1); I188V (1);
N189S (1); V264I (1); H275Y (5); S286G (16); E287K (1); N295S
(1); T332A (2); S388L (1); V394I (17), and E462G (1) (summarized
in Table S2). Most of these Canadian NA variant viruses were
sampled during wave 1. Polymorphisms in Canada were
numerous that delineated clades 5 through 7, namely NA V106I
(49) variants and N248D (48); however, these also appeared early
during the global pandemic [9]. Of note, all 16 S286G variants
were clade 2 (36% of Canadian clade 2 viruses; n=45 sampled)
isolated during wave 1 in BC (1), MB (11), NFL (3), and PQ (1).
Five of the Manitoba NA S286G variants were isolated during
outbreak weeks 08, 09, and 11 and were associated with severe
disease. The NA S286G variation was only seen with accompa-
nying co-variation in PB1 (K480R), which is located in the region
of PB1 that interacts with virus complementary RNA (cRNA) [18].
When analysis of positive selection was conducted, only two
viral sites located in HA (namely D222G/E and E374K) displayed
evidence of adaptive evolution, corresponding to the HA RBS and
Figure 3. Phylogenetic relationships for A/H1N1pdm viruses
sampled from Canada and globally. Phylogenetic tree inferred for
two hundred thirty five virus whole genomes sampled from Canada and
representative global reference genomes using the Neighbour-joining
(NJ) method. Scale bar indicates the number of nucleotide substitutions
per site. Colour-coding: clade 1 (not shown); clade 2 (orange); clade 3
(teal); clade 4 (yellow); clade 5 (green); clade 6 (blue), and clade 7 (pink).
doi:10.1371/journal.pone.0016087.g003
Figure 2. Spatial patterning of Canadian A/H1N1pdm viruses. Phylogenetic trees were inferred using the neighbour-joining distance
method, with genetic distances calculated by maximum likelihood using Kimura’s two-parameter model (K2P) in MEGA 4.0. The resultant consensus
tree was generated using the Summarization of Split Support on Phylogenetic Trees (SumTrees) program ver. 1.02. Lineages are colour-coded
according to the region of virus collection.
doi:10.1371/journal.pone.0016087.g002
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sampled Canadian viruses is encouraging from a public health
perspective. It also agrees with prior studies demonstrating that
little antigenic change occurs within a single influenza season and
that genetic diversity within seasons is stochastic via chance
introduction of divergent isolates [19]. Owing to HA antigenic and
receptor binding site overlap, the biological significance of HA-222
mutations remains controversial [20]. However, HA-222 is a key
determinant for virus binding to human-like receptors [14]. As
mentioned, HA-374 is located proximal to a region identified in
HA-neutralizing antibody structures that target a known antigenic
site in the HA stem region [16]. Lastly, a number of co-varying
amino acid substitutions were observed. As noted elsewhere, all
NA S286G clade 2 virus variants from 4 regions (BC, MB, NFL,
and PQ) co-varied with PB1 K480R. NA V394I co-varied with
PB1 N158S in 15/16 clade 7 viruses from AB. In addition, HA
Q293H (55 Canadawide) co-varied with HA K402T (37 Canada-
wide) in 36 clade 6 viruses in four regions (AB (1), MB (32), NB (2),
and SK (1)).
One virus of note was RV0062-10/2009. A clade 7 virus,
RV0062-10/2009 was collected during global outbreak week 36 in
wave 2 (December 5, 2009) as a tracheal aspirate from a
hospitalized case exhibiting severe respiratory illness. This virus
genome revealed confirmed heterozygote bases that caused coding
changes, namely, M1 Y240Y/F; M2 T11T/S; NA S35S/T, and
PB2 D567D/G (Table S2). All variations are unique amongst the
235 sequenced A/H1N1pdm viruses sampled from Canada and to
the best of our knowledge have not been reported elsewhere. The
NA-35 mutation is located at the terminus of the transmembrane
domain region associated with detergent-resistant lipid rafts [21].
Raft association may provide a critical determinant in targeting to
apical membranes. NA-35 also is proximal to a presumably
unstructured linker region (res 35–82) that connects the membrane
anchor to the catalytic NA domain (residues 83 to 469) [17].
RV0062-10/2009 matrix protein mutations occur in the
C-terminal fragment (165–254) of M1, which binds to vRNP
[22], and the external domain of M2 N-terminal domain that also
has been found to be under positive selection [23]. PB2 residues
538–676 form a compact, ordered domain with a novel fold [24].
PB2 residue 567 has previously been described as a major host
specificity determinant site that distinguishes avian and swine from
human isolates (Avian/Swine: charged residue aspartate (D);
Human: uncharged residue asparagine (N) (1918 H1N1, 1957
H2N2, 1977 H3N2) or isoleucine (I) [25]. These heterozygous
bases within RV0062-10/2009 imply that the associated infection,
which was severe, was probably a mixed influenza A/H1N1pdm
infection.
A/H1N1pdm infection severity does not trend with virus
genotype
As seen globally, A/H1N1pdm cases in Canada were
predominantly experienced as mild respiratory illness (Table S1).
Yet during Canada’s wave 1, A/H1N1pdm laboratory-confirmed
cases accounted for 1454 hospitalizations, 283 ICU admissions,
and 72 fatalities [26] and during wave 2, A/H1N1pdm lab-
confirmed cases accounted for 7081 hospitalizations, 1155 ICU
admissions, and 347 deaths [27]. When normalized for popula-
tion, the province of Manitoba (MB) and the Territory of Nunavut
(NU) were particularly hard hit with A/H1N1pdm cases requiring
hospitalizations (designated ‘‘severe’’) in wave 1 [28] (Table S3;
Source: FluWatch). Reasons for this are currently unknown [29].
Of the 158 (unique) viruses that were sequenced for which
infection status was known, 26.5% (42/158) required hospitaliza-
tion (Figure S1). Hence, to assess whether any particular virus
signatures might account for influenza infection severity, we
subjected the concatenated virus sequences to entropy-based
sequence variability analysis. Owing to observed predominance in
wave 2 of clade 7 viruses, we first independently analyzed wave 1
(n=133) viruses (Table 2). Analysis specific to wave 2 could not be
conducted owing to limited samples. A total of 6 A/H1N1pdm
sequence locations (PB2-480; PB1-158; HA-203; HA-293; NA-
394, and NS1-55) were observed with entropy differences greater
than background; but only 4 were significantly correlated with
clinical outcome as determined by Fisher Exact Test (in segment
order: PB2-480; HA-203; NA-394, and NS1-55) (Table 2).
Fewer HA-203 (T) variants were observed in the severe
population (P=0.009; Table 2). HA-S203T represents a clade 7-
defining variation located near the HA monomer-monomer
interface [12]. The small serine-to-threonine modification in side
chain appears not to have had a dramatic effect on HA structure
and introduction of the extra methylene group in the threonine
side chain may assist in stabilizing the loop region in its
surrounding environment [12]. Hence, perhaps the HA-203
mutation is advantageous for the virus and accounts for the
observed early global predominance of clade 7 viruses.
No NA V394I variants were encountered in the severe
population (P=0.041; Table 2). NA V394I was present in 16
clade 7 viruses (AB) and one clade 3 virus (PQ). In contrast, no
NS1-55 variants were detected in the mild case population
(P=0.042; Table 2); but only 3 total instances of this substitution
were observed (RV1767/09 (case unknown; PQ; wk 6; clade 2);
RV2018/09 (severe; MB; wk 9; clade 2); RV1975/09 (severe; MB;
wk 9; clade 2)). Influenza A NS1 protein acts to suppress the host
Table 1. Genetic diversity of A/H1N1pdm coding sequences
sampled in Canada.
Viral
Segment Gene
NT
a Substitutions
per Gene Site
AA
b Substitutions
per Protein Site
1 PB2 2.14610
24 2.32610
24
2 PB1 1.64610
23 1.47610
23
3 PA 2.09610
24 2.87610
24
4 HA 1.56610
23 1.98610
23
5 NP 1.65610
23 8.83610
24
6 NA 1.67610
23 2.36610
23
7 M1 4.15610
24 9.44610
25
7 M2 1.17610
24 1.74610
24
8 NS1 2.53610
24 6.19610
24
8 NEP (NS2) 9.32610
25 1.31610
24
aNT: nucleotide; in viruses sampled from 235 unique subjects;
bAA: amino acid; in viruses sampled from 235 unique subjects;
Viral segments exhibiting highest genetic diversity are highlighted in bold font.
doi:10.1371/journal.pone.0016087.t001
Figure 4. Temporal patterning of Canadian A/H1N1pdm viruses. Phylogenetic trees were inferred using the neighbour-joining distance
method, with genetic distances calculated by maximum likelihood using Kimura’s two-parameter model (K2P) in MEGA 4.0. The resultant consensus
tree was generated using the Summarization of Split Support on Phylogenetic Trees (SumTrees) program ver. 1.02. Clade distributions are colour-
coded according to 1, 3 or 5 week time periods corresponding to virus collection dates.
doi:10.1371/journal.pone.0016087.g004
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and virulence are documented [30]. Residue 55 is located within
the third alpha-helix (residues 54–70) of the dsRNA-binding
domain (RBD, residues 1–70) of NS1 [30]. Variation of NS1-55
from aspartate-to-glycine represents loss of a charged amino acid;
thus, may stabilize the coiled-coiled helical structure.
Lastly, more PB2-480 (I) variants were detected in the severe
population (P=0.029; Table 2). PB2 residue 480 is located within
the extreme carboxy-terminus of the cap-binding domain of PB2
(PB2cap: 318–483) [31]. PB2, along with PA, is involved in the
generation of 59-capped RNA primers through binding to and
endonucleolytic cleavage of host pre-mRNAs. The same cap-
binding domain also is required for PB2 binding interactions with
various human chaperone complex proteins, such as: chaperonin
CCT, stress-induced-phosphoprotein 1 (STIP1), Hsp70 and
Hsp90, FK506 binding protein 5 (FKBP5), and alpha- and beta-
tubulins [32]. Knockdown of CCT results in reduced growth of
influenza A/WSN/33 virus demonstrating that CCT plays an
important role in the virus life cycle, possibly by acting within a
multimeric host chaperone complex to aid folding, assembly and
transport of the virus RNA polymerase [32]. However, as only 5
total instances of this sporadic PB2-480 substitution were observed
nationally, RV2735/09 (case unknown; AB; wk 19; clade 7) and
the remainder regionally-isolated in MB [represented by
RV1964/09 (mild; wk 8; clade 6); RV1977/09 (severe; wk 8;
clade 6); RV1982/09 (severe; wk 8; clade 6) and RV2020/09
(severe; wk 9; clade 6)], the possibility of linked infections cannot
be excluded.
Manitoba was particularly hard hit with community-acquired
A/H1N1pdm infections [28,29]. As such, the MB region was well
sampled for virus sequencing and entropy-based sequence
variability analysis. MB clade 6 viruses accounted for 40 viral
sequences in our data set and 37.5% (15/40) required hospital-
ization, peaking during wave 1 in global outbreak weeks 9 and 10.
MB clade 7 viruses accounted for 34 viral sequences in our data
set, and 52.9% (18/34) required hospitalization, peaking in
November during wave 2. Such intensified regional sampling
may have introduced confounding bias in our severity analysis.
Thus to avoid founder effects, entropy analysis also was conducted
on the larger national data set for which infection status was
known, representing 158 unique viruses (Figure S1). A total of 7
A/H1N1pdm sequence variant locations (PB2-526; PB1-587;
PB1-158; HA-203; HA-383; NA-394, and NP-100) were observed
with entropy differences greater than background; but only 4 were
significantly correlated with clinical outcome as determined by
Fisher Exact Test (in segment order: PB1-158; HA-203; NA-394,
and NP-100) (Table S4). However, the predominance of clade 7
viruses that occurred in the wave 2 sampling period may have
skewed this analysis. Aside from the co-varying clade 7-marker loci
(HA-S203T and NP-V100I), we observed that PB1 N158S co-
varied with NA V394I in a regional manner (15/16 of the Alberta
NA V394I clade 7 viruses). Hence, we were unable to ascertain
with confidence whether any particular A/H1N1pdm virus
genotype trended with A/H1N1pdm infection severity in our
nationwide survey.
Discussion
On August 10 2010, the World Health Organization Director-
General announced that the pandemic influenza A (A/H1N1pdm)
novel reassortant virus had run its course and that the globe had
entered into a post-pandemic period [33]. Unpredictability of viral
mutations that arise during continued circulation in humans raises
concerns regarding future severity of infections and potential for a
continuing public health burden. Active molecular surveillance is
important to monitor the pathogenicity of circulating strains, and
to update pandemic preparedness and response plans accordingly.
This study contributes whole-genome sequences for A/H1N1pdm
viruses collected nationwide in Canada, providing additional
perspective (relative to the larger global data set) of the molecular
evolution of this emergent virus.
The first objective of our study was to acquire molecular insights
into the trajectory of A/H1N1pdm following its introduction into
Canada. Whole-genome sequences for 240 viruses (235 from
unique subjects) collected across the country over 33 weeks were
obtained,representingthelargestnationalstudyundertaken todate.
The chronological phylogeny for Canada revealed that five distinct
A/H1N1pdm viral lineages entered and co-circulated in Canada in
2009. The Canadian A/H1N1pdm virus genomes revealed no
evidence of further reassortment, and remained antigenically
related to the clade 01 A/California 07/2009 isolate. Clade 2
viruses were waning in Canada by A/H1N1pdm global outbreak
week 10; clade 6 viruses predominated in some regions during the
peak period for the outbreak’s wave1; but thereafter, clade 7 viruses
likely predominated nationwide (Figure 1; Table S2).
Early global predominance of clade 7 has been previously noted
[9]. The clade 7 marker variation S203T (S220T in H1
propeptide), observed in 81 of the 235 sampled Canadian viruses,
is located near the HA monomer-monomer interface [12]. Furuse
et al. observed that position 206 (H3 numbering) is a A/H1N1pdm
virus site under positive selection and also involved in antigenicity
Table 2. Entropy difference, with randomization test, between severe and mild sequence populations for A/H1N1pdm viruses
sampled in Canada (during Wave 1 only).
Nucleotide Position
a Protein Position
AA Consensus
(Mild/Severe)
AA Variance
(Mild/Severe) P-Value
b E-Score
c
01 PB2-1438 PB2-480 V (105/25) I (1/3) 0.030 0.029
02 PB1-473 PB1-158 N (92/28) S (12/0) 0.010 0.069
03 HA-604 HA-203 S (77/27) T (28/1) 0.010 0.009
04 HA-879 HA-293 Q (76/13) H (28/11) 0.030 0.140
05 NA-1180 NA-394 V (91/28) I (14/0) 0.010 0.041
06 NS1-164 NS1-55 E (106/26) G (0/2) 0.040 0.042
aNucleotide position on the coding sequence of each genome segment;
bP values were calculated from the randomization test on entropy score differences between severe and mild sequence populations;
cE-Scores were calculated from Fisher Exact Test; ,0.05 highlighted in bold font.
doi:10.1371/journal.pone.0016087.t002
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positive selection at HA-203. Moreover, selection would be
surprising in such a short time frame (,8 months) given the
limited immunity to A/H1N1pdm in the pre-vaccinated global
population except for cross-reactive immunity observed in some
elderly people [35].
The A/H1N1pdm virus has been simultaneously described as
having a high genome-wide evolutionary rate (3.66610
23
substitutions/site/year) [36] and a rate for the HA segment
(0.9610
23 substitutions/site/year) that represents the lowest of all
of the viral HAs of seasonal H1N1 (1918–1957; 2.9610
23),
seasonal H1N1 (1977–2009; 1.7610
23), and swine H1 (1930–
2009; 1.9610
23) [34]. However, elapsed time since A/H1N1pdm
emergence is too limited (8 months in our sampling period to
December 5, 2009) and precludes confident prediction of
evolutionary rate trends for this virus. We observed a high degree
of genetic conservation in terms of evolutionary distance
(substitutions per site) within the Canadian whole-genome data
set, which is in keeping with A/H1N1pdm virus emerging within
an immune-naı ¨ve population. Genetic variation was highest in the
segments encoding HA, NA and NP; however, most observed
variation is explained by the fixed clade 2, 5, 6, and 7- defining
marker variations (relative to ancestor sequences) in these three
genes (up to 5 per virus), namely HA (K-15E [K2E], Q293H
[Q310H]), and S203T [S220T]), NA (V106I and N248D), and
NP (V100I); (residue positions within square-brackets for HA
represent the H1 propeptide numbering scheme). In sum, our
genome data set supports the conclusion that A/H1N1pdm is
evolving but not excessively relative to other H1N1 influenza A
viruses.
Among the Canadian sampled viruses, we observed elevated
diversity in the PB1 segment, encoding RNA polymerase, that can
only be partially explained by variants that circulated regionally
[e.g., N158S (clade 7 - AB: 14 sequences); V157A (clade 2 - NS: 7
sequences); I181V and I535V (clade 2 - SK: 6 sequences); A587V
(clade 2 - NS: 13 sequences)]. Highest variability was observed in
clade 2 and clade 7 viruses within PB1 spanning residues 566
through 652; this PB1 region corresponds to the viral genomic
RNA (vRNA)-binding domain (residues 493–757) [37]. PB1
diversity is intriguing given that A/H1N1pdm represents a
reassortment of avian-like European swine genes (M1, M2, NA)
with a triple-reassortment strain previously circulating in swine
containing segments originally from the classical swine (NP, NS,
HA), (H3N2) human-lineage PB1, and the avian-lineage PA and
PB2 [36]. Previous studies have identified that compatibility
among viral ribonucleoprotein (vRNP) complex proteins (NP, PA,
PB1 and PB2) is necessary for optimal genome replication and
transcription, and can be restrictive in reassortant influenza viruses
[38–40]. Compensatory variations are often noted when a
suboptimal vRNP complex is introduced into a new host species
[18,39,41]. Although the A/H1N1pdm human-like PB1 gene and
avian-like PB2 and PA genes have circulated in pigs since 1997–98
as triple reassortant swine virus [42], avian-like signatures remain
for A/H1N1pdm PA and PB2 [25], suggestive of suboptimal
replication in human hosts. Rapid pandemic spread of A/
H1N1pdm may appear inconsistent with suboptimal host
adaptation; however, antigenic novelty of A/H1N1pdm HA and
NA proteins likely enabled the virus to overcome disadvantageous
replication. Our observation hints that adaptive mutations in PB1
may compensate for suboptimal replication of the predominantly
avian-like A/H1N1pdm polymerase complex.
It is worth noting that under new selective pressures, such as
oseltamivir antiviral treatment, recombinant viruses with en-
hanced viral polymerase activity have been found capable of
rapidly generating adaptive mutations that may enhance viral
fitness [40]. Increased polymerase activity has been implicated in
the extreme phenotype of the 1918 pandemic virus [43] and of
avian viruses adapted to mammalian cells [44]. Enhanced viral
polymerase activity also promotes replication and transcription of
viral RNA leading to increased surface accumulation of HA and
virus production [45]. Although we have no functional evidence to
suggest increased polymerase activity (nor infection severity)
associated with the detected Canadian PB1 variant viruses, further
assessment of PB1 variations is warranted, both in the context of
A/H1N1pdm transmission dynamics and virological properties.
Globally, 25% to 50% of severely ill A/H1N1pdm patients had
no coexisting medical conditions [5], and in Canada many of the
most ill were young, otherwise presumably healthy adults [29]. A
second objective of this study was to interrogate whether any viral
genome sites associated with increased infection severity. Although
there has been speculation that certain sporadic A/H1N1pdm
virus mutations may be associated with increased infection severity
[46–48], we did not find evidence to support this hypothesis in our
nationwide survey of circulating viruses over 33 weeks. For
example, HA D222E/G/N (also called 239) and HA Q293H (also
called 310) mutant viruses have been isolated worldwide from fatal
laboratory-confirmed A/H1N1pdm cases [48]. As residue 222
(also called 239) is located within the HA receptor binding cavity,
changes in this region could potentially influence virus binding and
internalization into host cells [14]. However, we detected only 5
variants within the HA 219–240 region (all of unknown case
status) during Canada’s wave 2 (outbreak weeks 28, 29, 30, 32 and
36) in BC, NB, ON, and PQ. And of the total of 59 (24.9%)
variants that were detected in the HA 301–316 region (wave 1
(51); wave 2 (8)), only 15 (25.4%) were associated with severe
infections, 11 with unknown case severity, and the remainder (33)
with mild cases. HA D222 mutations appear sporadically and
spontaneously. And despite the fact that A/H1N1pdm HA
D222E/G (and N) variant viruses have been detected in fatal
cases, the same mutation also has been detected globally in mild
A/H1N1pdm cases; conversely, viruses from numerous fatal cases
lack the mutation. Thus, the clinical and public health significance
of HA D222 variation remains unclear.
Notwithstanding the analysis of 133 unique wave 1 viruses and
158 wave 1 and 2 viruses (combined) for which infection status was
known, our findings did not reveal any linkages between virus
genotype and increased influenza infection severity. Although best
attempts were made to achieve rigorous virus selection; lack of
randomness in specimen sampling may have introduced bias (both
temporal and geographic) that precluded us from achieving
findings with significance. For example, we are aware that the
sequenced Canadian viruses associated with severe A/H1N1pdm
infections were not optimally distributed. Moreover, our entropy
analysis was restricted given large numbers of specimens (n=77)
for which infection status remained unknown. Thus, benefits of a
proactive and systematic process to link laboratory-generated
molecular data and epidemiological data for enhanced surveil-
lance purposes during such a pandemic were highlighted during
the course of this study.
All sampled Canadian viruses encoded the A/H1N1pdm
signature S31N (M2) allele that conveys antiviral resistance to
Amantadine. The neuraminidase H275Y (H274Y in N2 number-
ing) mutation known to confer resistance to oseltamivir (TamifluH)
and to peramivir, a drug used intravenously under an emergency
use authorization, also was detected but only sporadically (n=5)in
3 distinct clades/regions: namely clade 7 - AB (3); clade 3 - PQ (1)
and clade 6 - ON (1). All resistant cases were associated with
oseltamivir treatment. Such low frequency resistance is reassuring
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clinically-diagnosed A/H1N1pdm cases. This H275Y mutation
does not cause resistance to zanamivir (RelenzaH). Although recent
data suggests that oseltamivir-resistance does not alter viral fitness
and may induce severe disease at least in ferrets [49], the 5 cases
we detected (mild (2) and unknown (3)) contribute no further
insight on this issue.
Complete genome sequencing of influenza A viruses is essential
to determine the genetic basis of pathogenicity, antiviral resistance,
and to better understand viral evolution. We reconstructed whole-
genome sequences by conventional Sanger-based sequencing of
overlapping amplicons yielding a consensus assembly of the
sequence reads for each viral segment. However, influenza A virus
mutation rates during replication are estimated at ,1 nucleotide
change per 10,000 nucleotides [50] and most influenza infections
have 10–1000 associated virions possessing varying nucleotides in
their genomes, resulting in the generation of a viral ‘‘quasispecies’’
in which closely related but non-identical recombinant viral
genomes may co-circulate within a single host [3]. We acknowl-
edge that A/H1N1pdm consensus sequencing will describe only
the most dominant viral variant(s) within an intra-host population.
Therefore, other important intra-host genetic diversity (quasispe-
cies and mixed infections) may be underrepresented with this
conventional approach, and may account for why only one
example of a potential mixed infection during wave 2 (RV0062-
10/2009) was detectable. In some cases, wild type sequence has
been detected in nasopharyngeal swabs at the same time that
hemagglutinin sequence variants, particularly at HA residue 222
(also known as 225: H3 numbering), have been reported in deeper
lung specimens from the same patient [46,51]. Mixed infections
with multiple virus types can lead to reassortment and may have a
significant role in virus evolution. Furthermore, as more diverse
influenza viruses circulate with time and mixed infections increase,
potential for reassortment increases; thus, the adaptive evolution-
ary rate of A/H1N1pdm can be expected to accelerate with
potentially important public health consequences [52]. It remains
important to follow viral evolutionary trends, preferably applying
newer higher density sequencing technologies in order to detect
emerging variants with enhanced sensitivity and timeliness.
Our results (and those of others) underscore the complexity of
influenza A virus genetics and advocate for intensified global
surveillance applying whole-genome sequence data. Although
evaluating effects of vaccination on viral evolutionary trends and
vaccine efficacy over time are important, this study was not
designed to address such issues. Continued molecular surveillance
studies are indeed warranted to monitor A/H1N1pdm virus
genotypic and phenotypic diversity in the post-vaccination era,
providing information to enable timely epidemic or pandemic
detection, inform health policy decisions and influenza manage-
ment strategies, and to guide influenza vaccine development and
prioritization. With the advent of worldwide sentinel surveillance
in humans and animals as well as advances made in rapid whole-
genome sequencing, mathematical modeling, global alerting,
immunopathogenicity, and drug and vaccine therapeutics, public
health officials now have assembled necessary tools to intervene
effectively to prevent major morbidity and mortality from
influenza disease. Fortunately, this marks a major turning point
in the approach to management of influenza.
Materials and Methods
Viral culture
Virus specimens were collected from subjects with influenza-like
illnesses as part of the ongoing Canadian influenza surveillance
program. This program continuously monitors genetic and
antigenic changes in influenza viruses circulating in Canada. As
a national public health surveillance program, informed consent
from subjects is not required. However, as some additional
specimens were collected nationally from subjects that required
hospitalization and participated in specific H1N1-related studies,
ethics approval was acquired from the University of Manitoba
Health Ethics Board to investigate these viruses. For these patients,
written informed consent was obtained from each patient or their
surrogate. Specimens originated from eleven of the twelve
provinces and territories of Canada, namely Alberta (AB), British
Columbia (BC), Manitoba (MB), New Brunswick (NB), New-
foundland and Labrador (NFL), Nova Scotia (NS), Northwest
Territories (NWT), Nunavut (NU), Ontario (ON), Quebec (PQ),
and Saskatchewan (SK); missing: Yukon. For virus propagation,
50 mL of clinical specimens was inoculated into the Madin-Darby
canine kidney cell line (MDCK) (CCL34; American Type Culture
Collection, Rockville, Md.) and examined for cytopathic effect.
The MDCK cells were maintained in Eagles’s MEM containing
100 U/mL Penicillin, 100 mg/mL Streptomycin, 0.292 mg/mL
Glutamine, 25 mM Hepes buffer, 0.1 mM MEM non essential
amino acid, 1 mM MEM sodium pyruvate and 2 mg/mL TCPK-
trypsin. Cells were incubated at 37uCi naC O 2 incubator and
observed daily for cytopathic effect. Influenza A/H1N1pdm virus
was confirmed by molecular evaluation (i.e., real-time RT-PCR)
and antiviral sensitivities inferred from DNA sequences were
confirmed by phenotypic analyses.
Virus sequencing
A sum total of 240 A/H1N1pdm culture- and amplification-
positive clinical specimens were collected from 235 distinct
individuals and subjected to Sanger sequencing to generate
consensus assemblies for each virus segment (Table S1). A total
of 178 unique, consensus whole-genome sequences were derived
for A/H1N1pdm specimens from Canada’s wave 1 (defined as
April 16 to August 29 2009, inclusive); whereas 57 unique virus
genomes were acquired for Canada’s wave 2 (August 30 2009 to
December 5 2009 herein). These specimens were associated with
mild to severe (requiring hospitalization) influenza infections,
when known (n=158), and were distributed geographically and
temporally (Table S1).
The first A/H1N1pdm virus infection encountered in Canada
was sampled on April 16 2009 in Quebec (PQ), representing week
03 of the global outbreak (Figure S1; Table S1). Although regional
variation in laboratory-confirmed A/H1N1pdm cases occurred,
the nationwide incidence peak for wave 1 occurred during global
outbreak weeks 12 to 14 for most regions (range, 8-18) (Figure S2;
Table S5) [26]. The nationwide incidence peak for wave 2
occurred predominantly during global outbreak week 32 (range,
31–34) (Figure S2; Table S5) [27]. Thereafter, influenza activity
remained low through the beginning of 2010 (Figure S2); and on
January 27 2010 PHAC announced that wave 2 of pandemic A/
H1N1 2009 in Canada had tapered off [27].
The influenza A (H1N1) 2009 vaccine produced for Canada by
GlaxoSmithKline, called Arepanrix H1N1, was approved on
October 21 2009; and vaccinations began for high-risk groups on
October 26 2009 (representing week 31 of the global outbreak),
with the general public following thereafter (Figures S1 and S2).
Although vaccination status was unknown at sampling, only 17 of
the 240 sequenced viruses were sampled after initiation of
Canada’s vaccination campaign (including 2 redundantly-sam-
pled, severe A/H1N1pdm patients; Figure S1). However, only
11.6 million or 41% of Canadians (excluding the territories) aged
.12 years received vaccination during the entire A/H1N1pdm
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according to new self-reported data from the 2010 Canadian
Community Health Survey [53].
Where noted, specimens received as primary specimens or
Tissue Culture Fluid (TCF) extracts were directly processed.
Otherwise, viruses were first propagated in MDCK cells, as
described. Viral RNA was extracted, in the presence of supplied
carrier RNA, with the MagMAX
TM Viral RNA Isolation Kit
(Applied Biosystems, Foster City CA) using a MagMAX
TM
Express-96 Magnetic Particle Processor according to the manu-
facturer’s instructions. Extractions were performed on 140 mL for
the cultures and 265 mL for the primary specimens. Complemen-
tary DNA was synthesized by reverse transcription reaction, and
amplification by PCR was performed using specific primers for
each gene segment for a sum of 14 amplicons. RT-PCR reactions
were generated using the OneStep RT-PCR kit (Qiagen Inc.,
Mississauga, Canada) with either the universal influenza A generic
primer, Uni12, as reported elsewhere [54] or with A/H1N1pdm-
specific primers (Table S6). Reactions were performed using
BigDye-Terminator
TM v3.1 Cycle Sequencing Reaction Kit on a
3730 xl Genetic Analyzer (Applied Biosystems, Foster City, CA,
USA) following the manufacturer’s instructions. The A/
H1N1pdm viruses were bi-directionally sequenced across all
segments using 52 primer sets; the f1 and r1 primers for each
segment target the 59-start and 39-end of the coding region,
respectively (Table S6). Remaining primers in the series are
distributed at approximately 200 to 500-bp intervals. Sequences
were assembled, curated, and edited using LasergeneH v8.1
SeqMan Pro software (DNASTAR Inc., Madison, USA). RNA
was extracted from a total of 240 viruses sampled in Canada from
April 16 2009 to December 5 2009 (33 weeks) (Table S1). Passage
histories of the sequenced viruses are noted; A/H1N1pdm virus
propagation by cell culturing was required in all except 42 cases.
Five samples were redundantly sampled from the same individuals
to compare virus sequences: from primary specimens (designation,
p) versus cultured virus isolates (designation, i) (RV2076/09;
RV2042/09, and RV2066/09) or from two distinct anatomical
sites [RV2006-10/2009 (nasopharyngeal; NP) versus RV2007-10/
2009 (tracheal; TRA); RV2010-10/2009 (NP) versus RV2011-10/
2009 (TRA)]; no nucleotide differences were detected, indicating
that the A/H1N1pdm virus sequences were conserved. Hence, a
sum total of 235 unique whole-genome sequences were derived
from unique human subjects. Full genome sequences of all viruses
sequenced (n=240) are available for download (accession numbers
listed in Table S7).
Phylogenetic analysis
In addition to the Canadian human-isolated A/H1N1pdm virus
genomes sequenced in this study, other full-length sequences (10
coding sequences) available as of April 1 2009 to June 2 2010
(inclusive) (n=1198) sequences were downloaded from the influenza
sequence database (Influenza Virus Resource: http://www.ncbi.nlm.
nih.gov/genomes/FLU/FLU.html, accessed June 2, 2010). Acces-
sion numbers for the downloaded global genome references are
provided in Tables S8 and S9. Ten coding regions for the eight
genome segments for each virus were concatenated by an in-house
developed Perl script. Nucleotide alignments were constructed using
ClustalW [55] followed by manual alignment to codon position in
Molecular Evolutionary Genetics Analysis (MEGA) ver. 4.1 [56].
Phylogenetic trees were inferred using the neighbour-joining distance
method, with genetic distances calculated using Kimura’s two-
parameter model (K2P and bootstrapping test) in MEGA 4.0.
Confidence values for the branches were provided by bootstrap
analysis of 1000 replicates. Genetic Algorithm for Rapid Likelihood
Inference (GARLI) ver. 0.96 (http://www.nescent.org/informatics/
download.php?software_id=4, accessed June 2, 2010) also was
applied to infer or assess the reliability of the phylogenetic trees
[57]. In this method, rate variation across sites was estimated from a
gamma-distribution with non-parametric bootstrapping at 100
replicates. The resultant consensus tree was generated using the
Summarization of Split Support on Phylogenetic Trees (SumTrees)
program ver. 1.02, which is part of the DendroPy Phylogenetic
Computation Library ver. 2.6.1 [58]. Classification of representative
clades were based primarily on the classifications for related
sequences reported previously [9][59] but also on the bootstrapping
values (.70%) for distinguished branch lengths. Phylogenetic trees
were displayed using MEGA 4.0 and TreeView 1.6.6 [60] and
inspected manually.
Sequence analysis
Mutations within A/H1N1pdm genes were determined by
LasergeneH v8.1 SeqMan Pro software (DNASTAR Inc.,
Madison, USA) and displayed by Jalview v2.4.0 [61]. Identified
coding mutations within A/H1N1pdm genes of the Canadian
viruses were mapped to previously reported hemagglutinin
antigenic sites (Sa, Sb, Ca1/2, and Cb) [11] and neuraminidase
antigenic sites [17]. Genetic diversity of A/H1N1pdm genes was
estimated by Maximum Composite Likelihood (nucleotide) and
Dayhoff (amino acid) models in MEGA 4.0 [56]. An entropy
approach was used to compare two sequence populations and
identify the significant (P,0.05) amino acid differences with
randomization test [62]. A Fisher Exact Test was applied to infer
whether associations between genetic variations and A/H1N1pdm
disease were statistically supported. Sites exhibiting co-evolution-
ary associations were predicted by a Bayesian model, using
SPIDERMONKEY [63].
Identification of positively selected sites
A/H1N1pdm sites exhibiting positive selection were identified
using the codon-based maximum likelihood method, Fixed Effects
Likelihood (FEL) within the Hypothesis Testing Using Phylogenies
(HyPhy) package [64]. This was used to test the hypothesis as to
whether relative rates of nonsynonymous and synonymous
substitutions (dN/dS) at a given site differed between two datasets
along the phylogenetic tree. Before this analysis, an evolutionary
model was first estimated to fit the analyzed aligned sequences by
the Codon Model Selection (CMS) module.
Accession Numbers. Viral sequences from this study have
been deposited into GenBank (accession numbers in Supplemen-
tary Information, Table S7). Accession numbers for sequences
from global sources that were used in the generation of Figure 2
and 4 trees are listed in Table S8; accession numbers for sequences
from global sources that were used in the clade assignment for
Figure 3 are listed in Table S9.
Perl scripts. The in-house developed Perl scripts are avail-
able upon request.
Supporting Information
Figure S1 Regional and temporal distribution of
A/H1N1pdm viruses sequenced from Canadian prov-
inces and territories. X-axis displays the temporal distribution
of sampled viruses according to global outbreak week. Global
outbreak week 01 includes April 1 2009, the date of collection for
the first global A/H1N1pdm virus. Y-axis displays the Canadian
regional distribution; abbreviations: Alberta (AB), British Colum-
bia (BC), Manitoba (MB), New Brunswick (NB), Newfoundland
and Labrador (NFL), Nova Scotia (NS), Nunavut (NU), Northwest
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ewan (SK). Distribution of infection case status: When known, the
infection status associated with each virus is depicted with coloured
spheres: teal (mild); severe (red). Otherwise, unknown case status is
depicted with triangles (black).
(TIF)
Figure S2 Regional and temporal distribution of A/
H1N1pdm infections in Canada. A. National case incidence
according to the global outbreak initiated April 1 2009,
corresponding to the date of collection for the first global A/
H1N1pdm virus. B. Regional incidence for Canada during Wave
1. C. Regional incidence for Canada during Wave 2.
(TIF)
Table S1 Descriptions for A/H1N1pdm viruses sampled in
Canada.
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Table S2 Amino acid variations and clades detected for A/
H1N1pdm viruses sampled in Canada.
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Table S3 Cumulative hospitalized A/H1N1pdm cases in
Canada during Wave 1, by region.
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Table S4 Entropy difference, with randomization test, between
severe and mild sequence populations for A/H1N1pdm viruses
sampled in Canada (Wave 1 and 2, inclusive).
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Table S5 Summary of A/H1N1pdm infection incidence in
Canada.
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Table S6 Oligonucleotides used to amplify and sequence A/
H1N1pdm viruses in this study.
(DOC)
Table S7 Accession numbers for Influenza A/H1N1pdm viruses
sequenced in this study.
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Table S8 Accession numbers for the global outbreak A/
H1N1pdm virus reference sequences used for generating
Figures 2 and 4.
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Table S9 Accession numbers for the global outbreak A/
H1N1pdm virus reference sequences used for clade assignment
in Figure 3.
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